II. Epidemiology
- Primary Hyperparathyroidism is the most common cause of Hyperparathyroidism and mild Hypercalcemia- Often found in asymptomatic patients with a incidental High Serum Calcium
 
- 
                          Prevalence
                          - Women: 2-3 cases per 1000 women over age 65 years
- Men: 1 case per 1000 men over age 65 years
 
- Ages- Range: 40-70 years old
- Mean: 55 years old
 
III. Pathophysiology
- Overactive Parathyroid Glands (>=1 of 4 glands)
- Produce excessive Parathyroid Hormone (PTH)
- Results in disorder of bone metabolism
IV. Causes: Primary Hyperparathyroidism
- Single Parathyroid Adenoma (82 to 85%)
- Parathyroid Gland Hyperplasia or hypertrophy (15%)
- 
                          Parathyroid Malignancy  (rare, accounts for  0.5 to 3% of Primary Hyperparathyroidism)- Presents with severe Hypercalcemia, cervical Neck Mass, Laryngeal Nerve Palsy
 
- Familial Hyperparathyroidism (10-20%): Younger patients- Multiple Endocrine Neoplasia Type I (MEN I)
- Multiple Endocrine Neoplasia Type II (MEN II)
- Familial Hypocalciuric Hypercalcemia
- Hyperparathyroidism-Jaw Tumor Syndrome
- Neonatal severe Primary Hyperparathyroidism
 
- Other Parathyroid related causes- Lithium Therapy
- External neck Radiation Exposure
- Neck surgery with Parathyroid injury or resection
 
- Tertiary Hyperparathyroidism- Accelerated response to chronic Hypocalcemia (in advanced Renal Failure)
- Parathyroid over-produces PTH causing Hypercalcemia
 
V. Causes: Secondary Hyperparathyroidism
- Vitamin D Deficiency
- Decreased Calcium intake
- 
                          Renal Osteodystrophy
                          - Chronic Kidney Disease stage 4 or stage 5 and
- Decreased 1,25 dihydroxyvitamin D
- Hyperphosphatemia
- Hypocalcemia
 
- Normocalcemic Hyperparathyroidism (associated with 	Osteoporosis)- Diagnosis of exclusion after ruling-out Vitamin D Deficiency and Chronic Kidney Disease
 
VI. Symptoms
- See Hypercalcemia
- Asymptomatic Hypercalcemia (up to 80% of cases)
VII. Diagnosis
- Mnemonic (classic presentation is uncommon)- Stones
- Bones
- Abdominal groans
- Psychic moans
 
- 
                          Constellation of findings- See Hypercalcemia
- Calcium oxalate renal stones (Nephrolithiasis)
- Bony changes- Osteitis fibrosa
- Salt and pepper skull
- Bone resorption
 
- Acute Pancreatitis
- Psychosis and depression
 
VIII. Labs
- See Hypercalcemia for evaluation protocol
- 
                          Parathyroid Hormone (PTH) Level elevated- Measure Intact PTH
- See Parathyroid Hormone for algorithm
 
- Serum Electrolyte abnormalities- Hypercalcemia (Use Corrected Serum Calcium for Serum Albumin or Ionized Calcium)- Draw Fasting with minimal Occlusion
- Discontinue Thiazide Diuretics for 2 weeks before
- Repeat serum testing in 2 weeks if normal
 
- Hyperchloremia
- Hypophosphatemia
- Hypokalemia
 
- Hypercalcemia (Use Corrected Serum Calcium for Serum Albumin or Ionized Calcium)
- 
                          Urine Calcium
                          - Hypercalciuria (24 hour Urine Calcium and Urine Creatinine)
- If Urine Calcium low, consider Familial Hypocalciuric Hypercalcemia (rare) instead
 
- Renal Function tests
- Miscellaneous- 25 Hydroxyvitamin D
- 1,25 Dihydroxyvitamin D3
- Genetic Testing indications- CASR Gene Mutation
- Primary Hyperparathyroidism in age <40 years
- Familial Hypocalciuric Hypercalcemia
- Multiglandular disease (multiple Parathyroid Glands involved)
- Multiple Endocrine Neoplasia
 
 
IX. Imaging: Primary Hyperparathyroidism
- Classic XRay Findings- Skull XRay- "Salt and pepper" skull
 
- Chest XRay- Distal Clavicle resorption
 
- Hand XRay- Second and third middle phalange bone resorption
 
- Dental XRay- Bone resorption of Lamina dura around teeth
 
 
- Skull XRay
- Sestamibi Technetium Tc 99mParathyroid Scan- Test Sensitivity for localizing adenoma: 95%
- Causes of non-localizing scan- Ectopic PTH production
- Diagnostic error
- Four-gland hyperplasia
 
 
- End-organ evaluation
X. Differential Diagnosis
- See Hypercalcemia
- 
                          Familial Benign Hypocalciuric Hypercalcemia
                          - Does not improve with surgery, unlike primary disease
- Calcium to Creatinine ratio <0.01
 
XI. Management: Medical for Primary Hyperparathyroidism
- See Renal Osteodystrophy (Secondary Hyperparathyroidism)
- 
                          Hypercalcemic Crisis (Serum Calcium >14 mg/dl)- See Hypercalcemia for emergent management
 
- Indications for Non-surgical Management- Asymptomatic patients without surgical indications
- Serum Calcium level only mildly increased
- No prior life-threatening Hypercalcemia
- Normal Renal Function- Creatinine Clearance >70%
- No Nephrolithiasis
- No Nephrocalcinosis
 
- Normal Bone Mineral Density (Osteopenia or better)
 
- Avoid provocative factors- Thiazide Diuretics (although may be used in Nephrolithiasis prevention as below)
- Avoid Lithium
- Avoid Volume depletion (maintain hydration)
- Avoid prolonged bedrest or inactivity
- Avoid High Calcium diet
 
- Encourage moderate Physical Activity- Minimize bone resorption
 
- Encourage 64 ounces non-caffeinated fluid per day- Minimize risk of Nephrolithiasis
 
- Encourage moderate Calcium intake (1000 mg/day)- Low Calcium diet may surge Parathyroid Hormone
 
- Medications- Calcium Lowering Therapy- See Hypercalcemia for emergent Calcium lowering
- Calcimimetics- Cinacalcet (Senispar)
- Etelcalcetide (Parsabiv)
 
 
- Reduce bone resorption and increase Bone Mineral Density- Hormonal Therapy in Women (Postmenopausal)
- Bisphosphonates- Alendronate (Fosamax)
- Pamidronate
- Risedronate
- Zoledronic Acid
 
- Vitamin D Supplementation (400 to 800 IU/day, keep Vitamin D levels >20-30 ng/ml)
- Monoclonal Antibody- Denosumab (also used in Hypercalcemic Crisis to emergently lower Serum Calcium)
 
 
- Nephrolithiasis Prevention- Thiazide Diuretics (Chlorthalidone, Hydrochlorothiazide)- Decreases urinary Calcium and may reduce Nephrolithiasis risk
 
 
- Thiazide Diuretics (Chlorthalidone, Hydrochlorothiazide)
 
- Calcium Lowering Therapy
- Monitoring of medically managed patients- Every 12 month labs- Serum Calcium
- Serum Creatinine with estimated GFR
- Other annual testing if history or Nephrolithiasis- 24 hour Urine Calcium and Urine Creatinine
- Renal imaging
 
 
- Every 1-2 years- Bone Density (DEXA Scan)
 
 
- Every 12 month labs
XII. Management: Surgery (Parathyroidectomy) for Primary Hyperparathyroidism
- Precautions- Re-evaluate on a periodic basis
- Up to 15% of originally asymptomatic Hyperparathyroidism cases develop a surgical indication within 4.7 years
 
- Indications in Primary Hyperparathyroidism- Serum Calcium >12 mg/dl (or >1 mg/dl above the upper limit of normal)
- Hypercalcemic Crisis (Serum Calcium >14 mg/dl)
- Hypercalciuria (24 hour Urine Calcium >400 mg/dl/day)
- Osteoporosis (or T-Score <-2.5 at hip, spine or wrist)
- Osteitis fibrosa cystica
- Nephrolithiasis (including Incidental Imaging Findings)
- Nephrocalcinosis
- Young patient age (e.g. age <50 years)
- Exacerbating factors- Dehydration
- Immobile patient
 
- Creatinine Clearance <60 ml/min/1.73m2 or 30% below age-matched peers
- Persistent symptomatic Hypercalcemia (esp. neuromuscular)
 
- Efficacy- Successful in up to 95% of cases
- Few complications (up to 3.6% risk of Hypoparathyroidism)
- Normalizes PTH and Calcium levels
- Decreases Nephrolithiasis risk
- Decreases risk of worsening Renal Function
- Improves Bone Mineral Density
 
- Single Parathyroid Adenoma- Surgery to locate and remove adenoma
- Biopsy a second gland to rule out atrophy
 
- 
                          Parathyroid hyperplasia or hypertrophy- Remove 3.5 glands
- Autotransplant tissue into arm Muscle
 
XIII. Complications
- See Hypercalcemia
- Untreated Primary Hyperparathyroidism- Increased mortality
- Increased risk of cardiovaascular disease and Cerebrovascular Disease
- Increased risk of Nephrolithiasis and Renal Failure
- Increased Osteoporosis risk with decreased Bone Mineral Density
 
XIV. References
- Spiegel in Goldman (2000) Cecil Medicine, p. 1402-5
- (1991) Ann Intern Med 114:593-7 [PubMed]
- Bilezikian (2002) J Clin Endocrinol Metab 87:5353-61 [PubMed]
- Khan (2017) Osteoporos Int 28(1): 1-19 [PubMed]
- Sell (2022) Am Fam Physician 105(3): 289-98 [PubMed]
- Taniegra (2004) Am Fam Physician 69(2):333-40 [PubMed]
- Michels (2013) Am Fam Physician 88(4): 249-57 [PubMed]
